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Abstract
Background: Uric acid is the primary byproduct of purine metabolism. Hyperuricemia is associated with body
mass index (BMI), sex, and multiple complex diseases including gout, hypertension (HTN), renal disease, and type 2
diabetes (T2D). Multiple genome-wide association studies (GWAS) in individuals of European ancestry (EA) have
reported associations between serum uric acid levels (SUAL) and specific genomic loci. The purposes of this study
were: 1) to replicate major signals reported in EA populations; and 2) to use the weak LD pattern in African
ancestry population to better localize (fine-map) reported loci and 3) to explore the identification of novel findings
cognizant of the moderate sample size.
Methods: African American (AA) participants (n = 1,017) from the Howard University Family Study were included
in this study. Genotyping was performed using the Affymetrix
® Genome-wide Human SNP Array 6.0. Imputation
was performed using MACH and the HapMap reference panels for CEU and YRI. A total of 2,400,542 single
nucleotide polymorphisms (SNPs) were assessed for association with serum uric acid under the additive genetic
model with adjustment for age, sex, BMI, glomerular filtration rate, HTN, T2D, and the top two principal
components identified in the assessment of admixture and population stratification.
Results: Four variants in the gene SLC2A9 achieved genome-wide significance for association with SUAL (p-values
ranging from 8.88 × 10
-9 to 1.38 × 10
-9). Fine-mapping of the SLC2A9 signals identified a 263 kb interval of linkage
disequilibrium in the HapMap CEU sample. This interval was reduced to 37 kb in our AA and the HapMap YRI
samples.
Conclusions: The most strongly associated locus for SUAL in EA populations was also the most strongly associated
locus in this AA sample. This finding provides evidence for the role of SLC2A9 in uric acid metabolism across
human populations. Additionally, our findings demonstrate the utility of following-up EA populations GWAS signals
in African-ancestry populations with weaker linkage disequilibrium.
Background
In humans, uric acid is the primary byproduct of purine
metabolism and has long been associated with the devel-
opment of gouty arthritis [1,2]. Since the late 1800 s, it
has been postulated that hyperuricemia plays a role in
gout, kidney dysfunction, and vascular tone [3]. Over
the past several decades, evidence linking uric acid to
body mass index (BMI), insulin resistance, the metabolic
syndrome, [4,5], dietary intake of food substances high
in purine [1], dietary fructose intake [2,6,7], renal dis-
ease and hypertension [8-12] has been expanding.
Clustering of uric acid, gout, renal disease, and hyper-
tension has been known to have familial links since the
late 1800 s [11,12], suggesting a hereditary component
to these traits. Furthermore, varying levels of uric acid
in human populations, in addition to being attributable
to dietary habits, are likely the result of evolutionary
mutations that took place greater than 8 million years
ago [13,14]. These mutations have lead to the genetic
variation we see in modern human populations [1,15].
Mounting evidence generated from genome-wide asso-
ciation studies (GWAS) have linked uric acid to specific
genomic loci [4,16-18]. However, the GWAS reporting
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(PDZK1, GCKR, SLC16A9, SLC22A11, SLC22A12,
LRRC16A, WDR1, RAF1P1, ZNF5188,a n dABCG2),
have been conducted in individuals of European
[4,17,18], and Asian [19] descent. Given the paucity of
GWAS in populations of African-ancestry, we chose to
focus this manuscript on three main objectives in the
following order of priority 1) to replicate major signals
f o ru r i ca c i dr e p o r t e di nE Ap o p u l a t i o n s ;2 )t ou s et h e
weak LD patterns in African-ancestry populations to
better localize (fine-map) reported loci and 3) to explore
the identification of novel findings cognizant of the
moderate sample size as well as the higher rates of obe-
sity, renal disease, T2D, HTN, and decreased glomerular
filtration rate in African Americans [20].
Methods
Ethics Statement
Declaration of assurance of ethical conduct of research
was granted by the Howard University Institutional
Review Board. All participants provided written
informed consent for specimen collection and analysis.
This study adhered to the tenets of the Declaration of
Helsinki.
Study Sample
The study population has been described previously
[21]. Briefly, participants included in this study were
derived from the Howard University Family Study
(HUFS), a population-based study of related and unre-
lated African Americans from the Washington, D.C.
metropolitan area. The primary aims of HUFS included:
1) enrollment and examination of a randomly ascer-
tained sample of 350 African American families with
members in multiple generations from the Washington,
D.C. metropolitan area; 2) characterization of partici-
pants for anthropomorphic measures (including height,
weight, body composition measures and measures of
obesity, blood pressure and related physiological inter-
mediates, and diabetes-related and lipid-related vari-
ables); and 3) storing high-quality DNA to conduct
studies to identify genes or genomic regions linked and/
or associated with common, complex traits. Recruitment
was conducted via door-to-door canvassing, community
events, and advertisement in regional papers. A popula-
tion-based approach was used to establish an unascer-
tained sample with which to study multiple, common
diseases. In a second phase of recruitment, additional
unrelated individuals from the same geographic area
were enrolled to facilitate nested case-control studies.
Enrollment procedures (forms, measurements, and
laboratory assays) for unrelated individuals were identi-
cal to those for families. The total number of recruited
individuals was 2,028, of which 1,976 remained after
data cleaning. From this sample, we created a subset of
1,055 unrelated adults (≥ 20 years of age).
Phenotyping
A baseline physical examination and an interview-
based demographic questionnaire were conducted.
Blood was drawn for biochemical assays for creatinine,
glucose, uric acid, and several other molecular pheno-
types. Weight was measured on an electronic scale to
the nearest 0.1 kg with the participant wearing light
clothes. Height was measured with a stadiometer to
the nearest 0.1 cm with participants in bare feet. Body
mass index was calculated as (weight in kg)/(height in
m)
2. Blood pressure was measured while participants
were seated using an oscillometric device (Omron
Healthcare, Inc., Bannockburn, Illinois). The readings
were taken with a ten minute interval between read-
ings. Reported systolic and diastolic blood pressure
readings were the averages of the second and third
readings. Participants with systolic blood pressure ≥
140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or
on prescribed antihypertensive drug therapy were
defined as hypertensive. Serum creatinine levels were
estimated on fasting sample using the modified Jaffé
method. Estimated glomerular filtration (eGFR) was
calculated using the simplified Modification of Diet in
Renal Disease Study equation: eGFR = 186 × (serum
creatinine)
-1.154 ×a g e
-0.203(× 0.742 if female)(× 1.210 if
Black) [22]. EGFR was measured in ml/min/1.73 m
2
and creatinine was measured in mg/dl. Participants
with fasting plasma glucose ≥ 7.0 mmol (126 mg/dl)
were defined as having type 2 diabetes. Individuals
with prediabetes (fasting plasma glucose between 5.6
mmol and 7.0 mmol) were given unknown case/control
status. Serum uric acid levels were determined using
t h eC O B A SI n t e g r aU r i cA c i da s s a y ,v e r s i o n2( R o c h e
Diagnostics, Indianapolis, Indiana).
Genotyping
The Affymetrix
® Genome-Wide Human SNP array 6.0
was used to conduct genome-wide genotyping [23].
Genetic material was processed and hybridized accord-
ing to the manufacturer’s instructions. Following proces-
sing, the chips were scanned and genotype calls were
determined using the Birdseed 2 algorithm [23,24]. The
individual sample call rate had to be ≥ 95% for inclusion
(no samples excluded). SNPs with call rates < 95% (n =
41,885) across all individuals, minor allele frequency ≤
0.01 (n = 19,154), or a Hardy-Weinberg equilibrium
(HWE) test p-value < 1 × 10
-3 (n = 6,317) were
excluded. This analysis included the 808,465 autosomal
SNPs that passed these filters. The average call rate for
SNPs in this group of individuals was 99.5% and the
agreement of blind duplicates was 99.74%.
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Imputation of missing SNPs was performed using
MACH, version 1.0.16 http://www.sph.umich.edu/csg/
abecasis/MACH/[25] using a two stage approach. We
downloaded the HapMap combined phase II+III raw
genotype files for NCBI build 36, release 27 from
http://hapmap.ncbi.nlm.nih.gov/downloads/genotypes/
2009-02_phaseII+III/forward/non-redundant/[26]. For
both the CEU and YRI samples, we retained only those
individuals marked as founders. SNP inclusion criteria
f o ri m p u t a t i o nw e r et h a tt h e yh a daM A F≥ 0.01, a
missingness rate ≤ 5%, and an individual missingness
rate of ≤ 5%. These criteria resulted in 2,327,370 CEU
and 2,598,198 YRI reference SNPs. Imputation was
performed separately for these two reference panels. In
the first stage, haplotype phases for the reference data
were inferred using the settings -rounds 50 -states 200.
In the second stage, imputation was conditioned upon
the maximum-likelihood estimates of the crossover
map and the error rate map. Imputation error was
calibrated by ascertaining the threshold of posterior
probability associated with a 10% error rate for the
CEU reference panel and a 5% error rate for the YRI
reference panel averaged over 6,800 SNPs for which
we masked the experimentally determined genotypes.
Imputed genotypes had to pass quality control filters
requiring MAF ≥ 0.01, SNP missingness rate ≤ 10%,
and HWE test p-value ≥ 0.001. For imputed genotypes
that differed when using the CEU and YRI reference
panels, we accepted the imputed genotype using the
YRI reference panel. We successfully imputed
1,558,391 SNPs, yielding 2,366,856 experimentally
determined and imputed autosomal SNPs. Quality con-
trol and data management were performed using
PLINK, which is freely available and can be down-
loaded from http://pngu.mgh.harvard.edu/purcell/
plink/[27]. More detailed descriptions of these proce-
dures have been described previously [28,29].
Assessment of Population Stratification
Assessment of population stratification was done via
nonparametric clustering of genotypes using AWClust
[30]. From the sample of 1,055 unrelated individuals, 37
individuals were identified as outliers and were excluded
from analysis. Possible inflation of the type I error rate
due to population stratification was investigated using
genomic control [31]. EIGENSOFT was used to assess
population structure [32]. A previously published scree
plot [21] illustrates the two principal components (PCs)
used as covariates in the analysis.
Association Analysis
Of the 1,018 included participants, one was missing the
serum uric acid measurement, leaving a final analyzed
sample of 1,017 individuals. Descriptive and multivariate
analyses were conducted using R version 2.10.0 [33].
Serum uric acid values were not normally distributed.
Therefore, serum uric acid values were transformed
using a Box-Cox transformation (Box-Cox parameter
lambda = 0.54). In the multivariate analysis, serum uric
acid was analyzed for association with potential covari-
ates age, sex, BMI, T2D, HTN, and eGFR. In genetic
analysis, serum uric acid was analyzed as a continuous
variable using linear regression, adjusting for age, sex,
BMI, HTN, T2D, eGFR, and the first two PCs of the
g e n o t y p e sa sc o v a r i a t e s .P L I N K ,v e r s i o n1 . 0 7[ 2 7 ] ,w a s
used to conduct the association analyses.
Results
Clinical characteristics of the participants of our study
are displayed in Table 1. In the univariate analysis, age (p
=4 . 6 8×1 0
-9), sex (p =4 . 8 3×1 0
-35), BMI (p =6 . 9 8×1 0
-
7), eGFR (p =1 . 3 3×1 0
-26), HTN (p =6 . 9 3×1 0
-16), and
T2D (p = 0.021) were identified as significant covariates.
In the multivariate linear regression analysis, sex, BMI,
HTN, and eGFR (but not age and T2D) were significantly
associated with uric acid levels (Table 2). The distribu-
tion of p-values for genetic association with serum uric
acid is illustrated in Figure 1. The genomic control infla-
tion factor was 0.9964, indicating no inflation of the type
I error rate due to population stratification (Additional
File 1). The top 25 ranked SNPs unadjusted for covariates
are provided in Additional File 2 the 25 top ranked SNPs
adjusted for age and sex are provided in Additional File 3
while the top 25 ranked SNPs adjusting for all covariates
are provided in Additional File 4.
The four genome-wide significant associations were for
SNPs rs3775948, rs7663032, rs6856396, and rs6449213
(Additional File 4). These 4 SNPs were among the eleven
most frequently reported SNPs in SLC2A9 associated
with serum uric acid in European-ancestry populations
(Additional File 5) [16,34-40]. These four SNPs are all
located in a linkage disequilibrium (LD) block on chro-
mosome 4 (Figure 2) in the gene SLC2A9 (GeneID
56606). The next 8 highest ranking SNPs were also
located in SLC2A9 (Additional File 4). The association at
Table 1 Clinical characteristics of the African Americans
included in this study
Variable Mean (SD) or Percent
Age (yr) 48 (13)
Male 41%
Body Mass Index (kg/m
2) 30.5 (8.3)
Hypertension 50%
Type 2 Diabetes 15.6%
Glomerular Filtration Rate (ml/min/1.73 m
2) 105.1 (32.0)
Serum uric acid (mg/dl) 5.53 (1.64)
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our sample.
Serum uric acid levels were significantly different
between males and females (Wilcoxon rank sum test,
p =4 . 5 5×1 0
-35), with males having a mean serum uric
acid level of 6.25 mg/dl compared to 5.02 mg/dl for
females. The effect size estimates between females and
males at rs6449213 trended toward being significantly
different (Welch’s t-test, p = 0.068). The top 25 ranked
SNPs for serum uric acid in males and females, unad-
justed for covariates, are provided in Additional Files 6
and 7, respectively. The top 25 ranked SNPs for serum
uric acid, adjusted for age, BMI, hypertension, eGFR,
T2D, and the top two PCs, in males and females are
provided in Additional Files 8 and 9, respectively.
Fine Mapping
Using an r
2 cutoff of ≥ 0.3, LD with rs6449123 extends
across an interval of approximately 263 kb in the CEU
population and 231 kb in the YRI population.
Restricting the r
2 cutoff to ≥0.5, LD with rs6449213 in
the CEU population remains unchanged while, in sharp
contrast, the LD interval in YRI is reduced to approxi-
mately 37 kb. All of the 10 top ranking SNPs fall within
the 263 kb range; on the other hand, and quite remark-
ably 9 of the 10 top ranked SNPs lie within the 37 kb
interval and 3 out of the 4 SNPs that achieved genome-
wide significance lie in an approximately 1.3 kb interval
(Figure 3).
Discussion
Our findings replicate those of other investigators who
found association between variants in SLC2A9 and
SUAL [4,17,18,38]. To our knowledge, our study is the
first to report association between SLC2A9 and uric acid
in a large sample of admixed African Americans. The
high expression of SLC2A9 in the epithelial cells of the
proximal tubule and the atypical membranes of the kid-
neys [41], along with evidence that SLC2A9 is responsi-
ble for transport/re-absorption of uric acid and to a
lesser extent glucose and fructose [42], provides biologi-
cal plausibility for the high p-values for the SNPs in this
gene in association with uric acid levels.
Hyperuricemia has been implicated in multiple physio-
logic outcomes including hypertension and renal dys-
function. Hyperuricemia is suspected to influence the
development of hypertension via its role in vascular
endothelial cell dysfunction and activation of the renin-
angiotensin system [10]. Furthermore, experimental
models demonstrating the causative effects of hyperuri-
cemia in the development of hypertension were pro-
duced in rats with oxonic acid-induced hyperuricemia.
These rats developed salt-resistant hypertension after
induction of hyperuricemia, which resolved following
reduction of uric acid to normal levels [43].
Hyperuricemia has also been demonstrated to increase
the odds of developing acute renal dysfunction after car-
diovascular surgery and increased the odds of develop-
ing chronic renal disease 4-fold and 3-fold, respectively,
[44,45]. This information, coupled with evidence that
hyperuricemia causes epithelial dysfunction in renal ves-
sels [46], also supports the association we found
between higher uric acid levels and reduced eGFR. The
SNP rs6449213 has not only been associated with uric
acid levels but this association was demonstrated to be
influenced by sex and BMI [36], which may help explain
the associations we found between uric acid, sex, and
BMI in this study.
The findings of our fine-mapping analysis demonstrate
the advantage of using African-ancestry populations in
follow-up analyses of GWAS signals originally discov-
ered in European-ancestry populations. Replication ana-
lysis, using follow-up samples of increasing numbers of
individuals with European ancestry (more specifically,
Table 2 Multivariate linear regression between covariates
and serum uric acid levels
Variable b SE P-value
Age 0.0008 0.0018 0.665
Sex -0.6576 0.0405 8.30 × 10
-53
Body Mass Index 0.0190 0.0025 2.82 × 10
-14
Hypertension 0.2385 0.0441 8.17 × 10
-8
Type 2 diabetes -0.0161 0.0565 0.775
eGFR -0.0072 0.0007 4.76 × 10
-26
eGFR: estimated glomerular filtration rate.
Figure 1 Distribution of p-values from the multiple linear
regression of SNPs, associated with uric acid. The red line
indicates the genome-wide significance level 1 × 10
-8 and the blue
line indicates the suggestive significance level 1 × 10
-6.
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terns), allows for assessment of replication and refine-
ment of effect size estimates. In contrast, using follow-
up samples of individuals with ancestry differing from
the discovery sample (specifically, populations with
weaker linkage disequilibrium patterns) potentially
allows for resolution of the location of the GWAS sig-
nals through the weaker linkage disequilibrium patterns
in the follow-up population. Capitalizing on the weaker
linkage disequilibrium in African Americans compared
to EA populations, we were able to fine-map the
SLC2A9 signal from 263 kb to 37 kb.
Serum uric acid’s association with sex is confirmed in
our study. The association between decreased serum uric
acid and the effect allele of rs6449213 in SLC2A9 was sex-
specific, replicating the findings of other investigators
[36,37]. Specifically, rs6449213 reached genome-wide sig-
nificance in females but not in males. Given that
rs6449213 has a smaller effect on serum uric acid in males
than in females and that sex-stratified analysis reduces
sample size, it is possible that the lack of association of
rs6449213 with serum uric acid in males and the marginal
p-value for the test of effect size estimates in females vs.
males in our study both reflect false negatives finding.
A major limitation of our study is the moderate sam-
ple size compared to other GWAS studies. This suggests
that loci with small effects may have been missed. The
p a u c i t yo fG W A Sd a t ao nl a r g en u m b e r so fA f r i c a n -
Americans limits our ability to replicate our findings in
a population with a similar substructure at this time.
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Figure 2 Local genetic architecture. Association p-values from multiple linear regression are shown based on physical position (NCBI build 36,
dbSNP build 126). The light blue curve depicts the recombination rate from the combined Hap Map Phase II data. Linkage disequilibrium based
on the HUFS sample is color-coded red for r
2 to the top SNP ≥ 0.8, orange for r
2 < 0.8 and ≥ 0.5, blue for r
2 < 0.5 and ≥ 0.2, and gray for r
2 <
0.20. Green arrows indicate the direction of transcription.
Charles et al. BMC Medical Genomics 2011, 4:17
http://www.biomedcentral.com/1755-8794/4/17
Page 5 of 8Despite these limitations, it is noteworthy that we repli-
cated several of the reported association variants in the
gene, SLC2A9. The effect size of this association (2.6%
of the phenotypic variance averaged across sexes) is
large compared to those from GWAS in general [40]
but comparable to estimates from several studies of
individuals of European ancestry [16,35,38,39].
Conclusions
We found that SLC2A9 was significantly associated with
serum uric acid in this population-based sample of
African Americans, with a stronger effect in females
than in males. Additionally, we observed significant
association between uric acid levels and BMI, sex, eGFR,
and hypertension. These observations deserve more in-
depth evaluation in other human populations.
Additional material
Additional file 1: Supplementary Figure S1. Quantile-quantile plot for
genomic control. The red line indicates the expected distribution. The
inflation factor (lGC) is shown.
Additional file 2: Supplementary Table S1. Top 25 SNPs for serum uric
acid, unadjusted for covariates.
Additional file 3: Supplementary Table S2. Top 25 SNPs for serum uric
acid, adjusted for age and sex.
Additional file 4: Table 3. Top 25 SNPs for serum uric acid, adjusted for
age, sex, BMI, HTN, eGFR, T2D, and the top two PCs.
Additional file 5: Table 4. Previously reported GWAS associations
between specific SNPs and serum uric acid levels.
Additional file 6: Supplementary Table S3. Top 25 SNPs for serum uric
acid in males, unadjusted for covariates.
Additional file 7: Supplementary Table S4. Top 25 SNPs for serum uric
acid in females, unadjusted for covariates.
Additional file 8: Supplementary Table S5. Top 25 SNPs for serum uric
acid in males, adjusted for age, BMI, HTN, eGFR, T2D, and the top two
PCs.
Additional file 9: Supplementary Table S6. Top 25 SNPs for serum uric
acid in females, adjusted for age, BMI, HTN, eGFR, T2D, and the top two
PCs.
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